CONFERENCE PROGRAM AND SCHEDULE

Wednesday, September 16, 2015 4:05 p.m.-4:35 p.m. Refreshment Break Lenox Ballroom, Empire Ballroom, and Metropolitan 1:30 p.m.-1:35 p.m. Ballroom Foyer Welcome Metropolitan Ballroom 4:35 p.m.-6:35 p.m. Jill O’Donnell-Tormey, Research Institute, New York, NY Plenary Session 2: Tumor for Targeting: Insights from Genomics Metropolitan Ballroom 1:35 p.m.-2:05 p.m. Keynote Address Session Chairperson: Christoph Huber, Johannes Gutenberg Metropolitan Ballroom University Mainz Medical Center, Mainz, Germany

T cells as a drug for the personalized immunotherapy 4:35 p.m. Chairperson perspective of cancer Christoph Huber Steven A. Rosenberg, National Cancer Institute, Bethesda, MD 4:45 p.m. Personalizing Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO 2:05 p.m.-4:05 p.m. Plenary Session 1: Immune Regulation of 5:15 p.m. Targeting the mutanome for individualized T-Cell Responses/Evolving Concepts in Cancer cancer immunotherapy Immunology Ugur Sahin, TRON Translational Cancer Metropolitan Ballroom Center-Johannes Gutenberg University; BioNTech Biopharmaceutical New Technologies James P. Allison, The University of Session Chairperson: Corporation, Mainz, Germany Texas MD Anderson Cancer Center, Houston, TX 5:45 p.m. Impact of the immunogenic landscape of 2:05 p.m. Chairperson perspective: Immune checkpoint on immunotherapy blockade in cancer therapy: New insights, Hans-Georg Rammensee, University of opportunities, and prospects for a cure Tuebingen, Tuebingen, Germany James P. Allison 6:15 p.m. Durable complete response in a patient with 2:15 p.m. Biology of the PD-1 pathway metastatic melanoma following adoptive Arlene H. Sharpe, Harvard Medical School, transfer of autologous T cells recognizing 10 Boston, MA mutated tumor antigens* 2:45 p.m. Antitumor activity of immunomodulatory Todd D. Prickett, National Cancer Institute, antibodies Bethesda, MD Alan Korman, Bristol-Myers Squibb, Redwood City, CA 6:45 p.m.-8:45 p.m. 3:15 p.m. The interplay between L-arginine metabolism Reception and adoptive immunity in cancer Central Park and Lenox Ballroom Vincenzo Bronte, Venetian Institute of Molecular Medicine, Padova, Italy Poster Session A Empire Ballroom 3:45 p.m. Tumor-derived CD103+ dendritic cells carry to the tumor-draining lymph node Biomarkers and are essential for CD8+ T-cell priming* Clinical Trials of Cancer Immunotherapies Edward Roberts, University of California, San Francisco, CA Drug Development

*Proffered presentation

10 The Inaugural International Cancer Immunotherapy Conference

1506007_Immuno15Prog_front.indd 10 9/1/15 3:59 PM Immune Regulation of T-Cell Responses/Evolving Concepts 10:05 a.m. Refreshment Break in Cancer Immunology Central Park, Lenox Ballroom, and New York Ballroom Foyer Microbiome Other 10:35 a.m. Engineered T cells for cancer therapy Carl H. June, Abramson Cancer Center of the Preclinical Models University of Pennsylvania, Philadelphia, PA Tumor Antigens for Targeting: Insight from Genomics 11:05 a.m. Engaging T cells against cancer: BLINCYTO® Tumor Microenvironment and Cross Talk with the and beyond – the BiTE® platform Immune System Dirk Nagorsen, Amgen, Inc., Thousand Oaks, CA (not eligible for CME credit)

11:35 a.m. Combinatorial modalities with immune checkpoint blockade Thursday, September 17, 2015 F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA 7:00 a.m.-8:00 a.m. Continental Breakfast Central Park, Lenox Ballroom, and New York Ballroom Foyer 12:05 p.m.-1:35 p.m. Lunch Session: Roundtable Discussion: The Regulatory Landscape for Cell and Gene Therapy 7:45 a.m.-8:35 a.m Metropolitan Ballroom The 2015 William B. Coley Lectures Session Chairperson: Cedrik Britten, GlaxoSmithKline, Metropolitan Ballroom Stevenage, Hertfordshire, United Kingdom 7:45 a.m. Alexander Rudensky, Memorial Sloan Kettering Lunch will be served. Cancer Center, New York, NY Discussants: 8:10 a.m. Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA Gwendolyn Binder-Scholl, Adaptimmune LLC, Oxon, United Kingdom 8:35 a.m.-12:05 p.m. Cedrik Britten Plenary Session 3: Clinical Trials of Elma Hawkins, Lion Biotechnology, New York, NY Cancer Immunotherapies, Part 1 Metropolitan Ballroom Robert Hawkins, Cancer Research UK Manchester Institute, Manchester, United Kingdom Session Chairperson: Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA Thomas Hinz, Paul-Ehrlich-Institut, Langen, Germany 8:35 a.m. Combination checkpoint blockade Laura Johnson, University of Pennsylvania, Philadelphia, PA Jedd D. Wolchok, Memorial Sloan Kettering Carl June, Abramson Cancer Center of the University of Cancer Center, Ludwig Cancer Research, Pennsylvania, Philadelphia, PA New York, NY 9:05 a.m. Treating the tumor and treating the host Michael Kalos, Lilly, New York, NY Ronald Levy, Stanford University School of David Lebwohl, Novartis Pharmaceuticals Corporation, Medicine, Stanford, CA Florham Park, NJ

9:35 a.m. Designing immunostimulatory mAb to Celia Witten, Center for Biologics Evaluation and Research, promote anticancer immunity FDA, Rockville, MD Martin J. Glennie, University of Southampton, Southampton, United Kingdom

*Proffered presentation

TRANSLATING SCIENCE INTO SURVIVAL • Program and Proceedings 11

1506007_Immuno15Prog_front.indd 11 9/1/15 3:59 PM CONFERENCE PROGRAM AND SCHEDULE

12:05 p.m.-1:35 p.m. Friday, September 18, 2015 Lunch Central Park and Lenox Ballroom 7:00 a.m.-8:00 a.m. Continental Breakfast 1:45 p.m.-5:15 p.m. Central Park, Lenox Ballroom, and New York Ballroom Foyer Plenary Session 4: Tumor Microenvironment and the Cross Talk Between Immune/ Inflammatory Cells and the Tumor Stroma, 7:00 a.m.-8:00 a.m. Matrix, and Vasculature Meet the Editors Metropolitan Ballroom Central Park

Session Chairperson to be announced Cancer Immunology, Immunotherapy Graham P. Pawelec, Editor-in-Chief 1:45 p.m. Chairperson perspective Speaker to be announced Suzanne Ostrand-Rosenberg, Editor-in-Chief

1:55 p.m. Inflammation and cancer: Immune cells as Cancer Immunology Research Robert D. Schreiber, Editor-in-Chief targets for anticancer therapy Lisa Coussens, Oregon Health & Science Philip D. Greenberg, Editor-in-Chief University, Portland, OR Linda J. Miller, Executive Editor

2:25 p.m. Therapy-induced anticancer OncoImmunology Guido Kroemer, Editor-in-Chief immunosurveillance: The example of Laurence Zitvogel, Editor-in-Chief successful chemotherapies Guido Kroemer, Cordeliers Research Center Lorenzo Galluzzi, Editor-in-Chief (INSERM) - Institut Gustave-Roussy, Villejuif, France 8:00 a.m.-9:40 a.m. 2:55 p.m. Tumor stroma: Immunomodulatory functions Plenary Session 5: Immunotherapy of Persistent and a target of immunotherapy Viral Infections and Virus-1 Induced Cancers Ellen Puré, University of Pennsylvania School of Metropolitan Ballroom Veterinary Medicine, Philadelphia, PA Session Chairperson: Cornelis J.M. Melief, Leiden University 3:25 p.m. Refreshment Break Medical Center and ISA Pharmaceuticals BV, Leiden, Central Park, Lenox Ballroom, and New York The Netherlands Ballroom Foyer 8:00 a.m. Chairperson perspective 3:55 p.m. Regulation of T-cell homing in tumors Cornelis J.M. Melief George Coukos, Ludwig Center for Cancer Research-University of Lausanne, Lausanne, 8:10 a.m. Properly timed chemo-immunotherapy of cancer Sjoerd Henricus van der Burg, Leiden University Switzerland Medical Center, Leiden, The Netherlands 4:25 p.m. Cancer subtypes and their immune 8:40 a.m. Immunotherapy with virus-specific T cells microenvironments Helen Heslop, Baylor College of Medicine, Wolf Herve Fridman, Cordeliers Research Houston, TX Center (INSERM), Paris, France 9:10 a.m. T-cell memory and exhaustion 4:55 p.m. Hypoxia is an essential driver of immune Rafi Ahmed, Emory University, Atlanta, GA suppression in the tumor microenvironment* Michael A. Curran, The University of Texas MD Anderson Cancer Center, Houston, TX

*Proffered presentation

12 The Inaugural International Cancer Immunotherapy Conference

1506007_Immuno15Prog_front.indd 12 9/1/15 3:59 PM 9:40 a.m.-10:10 a.m. 1:45 p.m. Imaging immunity: Creating a quantitative Refreshment Break spatiotemporal understanding of host Metropolitan East and West Foyer defense and antitumor responses Ronald N. Germain, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD 10:10 a.m.-12:40 p.m. Plenary Session 6: Biomarkers Metropolitan Ballroom 12:40 p.m.-2:10 p.m. Lunch Ira Mellman, Genentech, Inc., Session Chairperson: Central Park and Lenox Ballroom South San Francisco, CA

10:10 a.m. Chairperson perspective: Biomarkers and mechanism in immunotherapy 2:25 p.m.-4:25 p.m. Ira Mellman Concurrent Session 1: Microbiome Room TBD; see program addendum 10:40 a.m. Immune checkpoint therapy: Immune monitoring on presurgical and tissue-based Session Chairperson to be announced clinical trials 2:25 p.m. Chairperson perspective Padmanee Sharma, The University of Texas MD To be announced Anderson Cancer Center, Houston, TX 2:35 p.m. Gut microbiota regulates anticancer 11:10 a.m. Antigenome and immune contexture in cancer immune responses Jerome Galon, INSERM, Paris, France Laurence Zitvogel, Gustave Roussy Cancer 11:40 a.m. Genomic assessment of tumor immune profiles Center, Villejuif, France Christian Ottensmeier, University of 3:05 p.m. Commensal microorganisms and polymorphic Southampton, Southampton, United mucosal surfaces determine the evolution of Kingdom distal metastatic tumors 12:10 p.m. Tumor-expressed IDO recruits and activates Jose R. Conejo-Garcia, The Wistar Institute, MDSCs in a Treg-dependent manner Philadelphia, PA Rikke B. Holmgaard, Memorial Sloan Kettering 3:35 p.m. Biofilms, genetics, and colon cancer Cancer Center, Ludwig Cancer Research, Cynthia L. Sears, Johns Hopkins University, New York, NY Baltimore, MD

4:05 p.m. Tracking microbial sensing in colorectal 12:40 p.m.-2:10 p.m. cancer using bioorthogonal click chemistry* Lunch Session: Imaging and Targeting of Jason Hudak, Harvard Medical School, the Antitumor Response Boston, MA Metropolitan Ballroom

12:55 p.m. Immunological insights from tracking dynamic cellular behavior in lymph nodes and tissues Alex Yee-Chen Huang, Case Western Reserve University School of Medicine, Cleveland, OH

1:20 p.m. Towards synthetic immune cells for cancer immunotherapy Carl G. Figdor, Nijmegen Centre for Molecular Life Sciences (NCMLS), Nijmegen, The Netherlands

*Proffered presentation

TRANSLATING SCIENCE INTO SURVIVAL • Program and Proceedings 13

1506007_Immuno15Prog_front.indd 13 9/1/15 3:59 PM CONFERENCE PROGRAM AND SCHEDULE

2:25 p.m.-4:25 p.m. Immunotherapy of Persistent Viral Infections and Virus-1 Concurrent Session 2: Companion Diagnostics: Induced Cancers Assay Harmonization Preclinical Models Room TBD; see program addendum Trials in Progress (promising ongoing trials or unique trial Axel Hoos, GlaxoSmithKline Session Chairperson: designs that have not yet yielded results) Pharmaceuticals, Collegeville, PA Tumor Microenvironment and Cross Talk with the 2:25 p.m. Introduction Immune System Axel Hoos

2:35 p.m. Abigail McElhinny, Ventana Medical Systems, Inc., Tucson, AZ

2:45 p.m. Robert A. Anders, Johns Hopkins University Saturday, September 19, 2015 School of Medicine, Baltimore, MD

3:05 p.m. Paul Tumeh, UCLA Medical Center, 7:00 a.m.-8:00 a.m. Los Angeles, CA Continental Breakfast 3:25 p.m. Kenneth Bloom, GE Healthcare, Aliso Viejo, CA Central Park, Lenox Ballroom, and New York Ballroom Foyer

3:45 p.m. Panel Discussion Robert A. Anders 8:00 a.m.-10:00 a.m. Kenneth Bloom Concurrent Session 3: Preclinical Models Axel Hoos Room TBD; see program addendum Ian McCaffery, Genentech, South San Francisco, CA Session Chairperson: Philip D. Greenberg, Fred Hutchinson Abigail McElhinny Cancer Research Center, University of Washington, Jim Novotny, Bristol-Myers Squibb, Princeton, NJ Seattle, WA Reena Philip, Food and Drug Administration 8:00 a.m. Chairperson perspective Center for Devices and Radiological Health, Philip D. Greenberg Silver Spring, MD Dave Stanforth, Dako North America - Agilent 8:10 a.m. Modeling combination immunotherapy Technologies, Carpinteria, CA studies on CNS melanoma Paul Tumeh Charles G. Drake, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

4:45 p.m.-6:45 p.m. 8:40 a.m. Designing combination immunotherapies Reception to drive synergistic innate and adaptive Central Park and Lenox Ballroom antitumor immunity Poster Session B Darrell J. Irvine, MIT Koch Institute for Empire Ballroom Integrative Cancer Research, Cambridge, MA

Companion Diagnostics: Assay Harmonization 9:10 a.m. Engineered T-cell receptor-based therapy of pancreatic ductal adenocarcinoma Drug Development Ingunn M. Stromnes, Fred Hutchinson Cancer Imaging and Targeting of the Antitumor Response Research Institute, University of Washington, Seattle, WA Immune Regulation of T-Cell Responses/Evolving Concepts in Cancer Immunology

*Proffered presentation

14 The Inaugural International Cancer Immunotherapy Conference

1506007_Immuno15Prog_front.indd 14 9/1/15 3:59 PM 9:40 a.m. TGF-beta1 primed myeloid derived 10:30 a.m.-1:00 p.m. suppressor cells decrease tumor growth and Plenary Session 7: Clinical Trials of Cancer lose their ability to inhibit T-cell proliferation Immunotherapies, Part 2 via iNOS downregulation* Metropolitan Ballroom Padmini Jayaraman, Baylor College of Robert H. Vonderheide, Abramson Medicine, Houston, TX Session Chairperson: Cancer Center of the University of Pennsylvania, Philadelphia, PA

8:00 a.m.-10:00 a.m. 10:30 a.m. Mechanisms of protective tumor immunity Concurrent Session 4: Drug Development: Glenn Dranoff, Novartis Institutes for Immuno-Oncology Trial Design BioMedical Research, Cambridge, MA Room TBD; see program addendum 11:00 a.m. Cancer prevention: Dendritic cell enhanced Session Chairperson: Axel Hoos, GlaxoSmithKline immune responses towards neoantigens in Pharmaceuticals, Collegeville, PA patients with Lynch syndrome Jolanda deVries, Centre for Molecular Life 8:00 a.m. PD-1 directed antibody: A broad-based Sciences, Nijmegen, The Netherlands antineoplastic therapy Roy Baynes, Merck Research Laboratories, 11:30 a.m. Prospect of a vaccine to prevent cancer in Rahway, NJ BRCA1-2 carriers Robert H. Vonderheide 8:30 a.m. Title to be announced Daniel S. Chen, Genentech, Inc., South San 12:00 p.m. Towards implementation of T-cell therapy in Francisco, CA pancreatic cancer Rienk Offringa, Deutsches 9:00 a.m. Title to be announced Tai-Tsang Chen, Bristol-Myers Squibb, Krebsforschungszentrum, Heidelberg, Germany Wallingford, CT 12:30 p.m. Nonviral gene transfer to redirect T-cell 9:30 a.m. Title to be announced specificity Axel Hoos Laurence J.N. Cooper, The University of Texas MD Anderson Cancer Center, Houston, TX

1:00 p.m. Departure 10:00 a.m.-10:30 a.m. Refreshment Break Central Park and Lenox Ballroom

*Proffered presentation

TRANSLATING SCIENCE INTO SURVIVAL • Program and Proceedings 15

1506007_Immuno15Prog_front.indd 15 9/1/15 3:59 PM